GLP-1 medications for weight-loss: a triumph of marketing over patient care

GLP-1 weight loss drugs are receiving an avalanche of positive press. From major media outlets to trade publications, clinical, policy, and lay audiences have been inundated with articles declaring them to be “miracle drugs.” This messaging has largely been constructed by the drugs’ manufacturers, often supported with quotes from doctors and researchers holding significant, undeclared financial entanglements with the manufacturers. The peer-reviewed research underpinning the efficacy and safety of these drugs also uses misleading reporting practices to obscure less positive findings. As such, this information may not be seen by reviewers, policy makers, clinicians, or the public. This paper will examine and critique the literature on GLP-1 medications for weight loss. We begin by briefly describing the mechanism of action and their evolution from diabetes medications to “weight management.” We then provide a narrative review of the efficacy and safety data from the Phase 3, double-blind, randomized controlled trials of the two most popular GLP-1-based drugs currently available for weight loss – semaglutide and tirzepatide, highlighting misleading reporting practices. We also describe conflicts of interest among research authors, media proponents, and “patient advocacy” groups, as well as documented regulatory misconduct in the marketing of these drugs. This analysis will provide readers with more clear, comprehensive, and accurate information than is currently easily accessible, allowing for improved public and healthcare discourse and informed consent around these drugs.